Case Studies in the Identification and Management of IBD
Gastroenterology
Curriculum:
Evolving Diagnostic and Treatment Strategies in Inflammatory Bowel Disease
Evolving Diagnostic and Treatment Strategies in Inflammatory Bowel Disease
Credits:
0.5 AANP Contact Hours 0.5 AMA PRA Category 1 Credit(s) ™
0.5 AANP Contact Hours 0.5 AMA PRA Category 1 Credit(s) ™
Launch Date:
April 04, 2017
April 04, 2017
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Primary care physicians; gastroenterologists; nurse practitioners (NPs); physician assistants (PAs); and other clinicians.
Relevant Terms:
Inflammatory bowel disease; Crohn's disease; ulcerative colitis
Gerald Dryden, MD, PhD
Gerald W. Dryden, MD, PhD Professor of Medicine and Bioengineering Director, Clinical Trials Unit University of Louisville Louisville, KY
Bio
Dr. Gerald W. Dryden is a Professor of Medicine and Bioengineering and the Director of the Clinical Trials Unit at the University of Louisville. He joined the faculty of the University of Louisville after completing his residency, fellowship and obligated service with the US Navy. Dr. Dryden has been a practicing gastroenterologist for 17 years, and has had a focus in inflammatory bowel disease and GI immunology for the past 10 years. He also has a strong interest in innovation and improving clinical practice.
Dr. Dryden’s undergraduate degree, a Bachelor of Science in Agronomy, was earned from the University of Kentucky College of Agriculture. He then graduated from the University of Kentucky College of Medicine and began an eight-year period of active duty service with the US Navy. While in the Navy, he completed a residency in Internal Medicine and a fellowship in Gastroenterology. During his tenure at the University of Louisville, he received additional training, including a Master of Science in Public Health, a Master of Science in Microbiology and Immunology and a PhD in Microbiology and Immunology.
Millie D. Long, MD, MPH
Millie D. Long, MD, MPH
Associate Professor of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC
Bio
Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia, where she was a Bowman Scholar. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina at Chapel Hill. While at University of North Carolina, she also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine and gastroenterology. She is currently Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina. Her clinical practice is based at the University of North Carolina Inflammatory Bowel Diseases Center.Dr. Long’s interests include research on prevention of complications of inflammatory bowel disease and women’s health. She is currently an investigator for the CCFA Partners cohort, a prospective cohort focusing upon patient reported outcomes that includes over 14,000 patients living with inflammatory bowel disease. Dr. Long has contributed numerous peer-reviewed publications, book chapters, and review articles to the medical literature. She currently serves as an invited reviewer for journals such as Inflammatory Bowel Diseases, Gastroenterology, and the American Journal of Gastroenterology. She is Associate Editor for the IBD section of the American Journal of Gastroenterology.
| 1. | Recognize the conditions referred to as inflammatory bowel disease (IBD), and evaluate the degree of severity based on clinical measures of disease activity | 2. | Match appropriate pharmacologic therapeutic strategies to clinical IBD presentations to maximize outcomes while minimizing toxicity |
| 3. | Identify patients who are at high risk of complications from IBD and who may benefit from new mechanisms of action in IBD therapy | 4. | Employ approaches to optimize benefits from IBD treatment options and facilitate adherence |
| 1. | Recognize the conditions referred to as inflammatory bowel disease (IBD), and evaluate the degree of severity based on clinical measures of disease activity |
| 2. | Match appropriate pharmacologic therapeutic strategies to clinical IBD presentations to maximize outcomes while minimizing toxicity |
| 3. | Identify patients who are at high risk of complications from IBD and who may benefit from new mechanisms of action in IBD therapy |
| 4. | Employ approaches to optimize benefits from IBD treatment options and facilitate adherence |
Planning Committee
Gregg Sherman, MD
Family Practice
Plantation, FL
Harvey C. Parker, Ph.D., CCMEP
National Association for Continuing Education
Plantation, FL
National Association for Continuing Education
Plantation, FL
Joshua Kilbridge
President, Creative Director
Kilbridge Associates
San Francisco, CA
Kilbridge Associates
San Francisco, CA
PROGRAM OVERVIEW:
Inflammatory bowel disease (IBD) is a term that encompasses chronic inflammatory disorders of the bowel, the most common of these being ulcerative colitis (UC) and Crohn's disease (CD). As many as 1.5 million persons in the United States may suffer from IBD accounting for over 700,000 physician visits, 100,000 hospitalizations, and disability in 119,000 patients every year in the United States. IBD is associated with an overall health care cost of more than $1.7 billion and adversely affects the quality of life of both patients and their families.
This program will help to bridge the knowledge and performance gaps related to identification, and management of Inflammatory Bowel Disease. This educational initiative offers a two-phased curriculum. Phase 1 offered a Self Assessment Program (SAP) to allow learners to assess their knowledge and skills in this area, compare their selections and scores with all other learners to date, and review commentary from the faculty. This is the Phase 2 activity in the program, and utilizes a case-based interactive structure focused on educational drivers identified in Phase 1.
DISCLOSURE POLICY STATEMENT:
It is the policy of NACE to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. NACE assesses conflict of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter's content for fair balance and absence of bias, scientific objectivity of studies utilized in this activity, and patient care recommendations.
While NACE endeavors to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice.
DISCLOSURE OF CONFLICTS OF INTEREST:
Faculty
Gerald W. Dryden, MD, MSPH, MSc, AGAF, FASGE, Course Director, has the follow to disclose: serves on the speaker’s bureaus of Abbvie, Takeda, EnteraHeatlh and Salix. Dr. Dryden also conducts contracted research for Abbvie, Johnson & Johnson, Merck, Takeda, Pfizer, and Genetech.
Millie D. Long, MD, MPH, serves as a consultant for Abbvie, Pfizer, Takeda and Theravance.
Planning Committee
Gregg Sherman, MD, has no real or apparent conflicts of interest to report.
Harvey Parker, PhD, has no real or apparent conflicts of interest to report.
Josh Kilbridge has no real or apparent conflicts of interest to report.
DISCLOSURE OF UNLABELED USE:
NACE requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of NACE. The information is presented for the purpose of advancing the attendees' professional development.
For CME questions, please contact: NACE at info@naceonline.com
Contact this CME provider for privacy and confidentiality policy statement information at:
http://www.naceonline.com/privacy_policy.php
ACCREDITATION STATEMENT:
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Association for Continuing Education designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This Enduring Material activity, Evolving Diagnostic and Treatment Strategies in Inflammatory Bowel Disease: Targeting Learning to Close Gaps and Improve Outcomes, has been reviewed and is acceptable for Prescribed credit by the American Academy of Family Physicians. Term of approval begins 09/15/2016. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 0.5 contact hours of continuing education (which includes 0.25 hrs of pharmacology).
The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 0.5 contact hours of continuing education (which includes 0.25 hrs of pharmacology).
TO OBTAIN CME CREDITS:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit.
- Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit.
- You must score 60% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE FORMAT/MEDIUM: Internet CME Activity
ESTIMATED TIME TO COMPLETE: 30 minutes
ACKNOWLEDGEMENT:
This activity is sponsored by National Association for Continuing Education.
This educational activity is supported by an educational grant from Shire.
If you have any questions regarding this activity, send an email to info@naceonline.com.
Copyright © 2017 National Association for Continuing Education. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of NACE is prohibited.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
© 2007-2025 HealthCourse, Inc. All rights reserved.
